Correlation Between Phathom Pharmaceuticals and Replimune

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Phathom Pharmaceuticals and Replimune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Phathom Pharmaceuticals and Replimune into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Phathom Pharmaceuticals and Replimune Group, you can compare the effects of market volatilities on Phathom Pharmaceuticals and Replimune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Phathom Pharmaceuticals with a short position of Replimune. Check out your portfolio center. Please also check ongoing floating volatility patterns of Phathom Pharmaceuticals and Replimune.

Diversification Opportunities for Phathom Pharmaceuticals and Replimune

-0.51
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Phathom and Replimune is -0.51. Overlapping area represents the amount of risk that can be diversified away by holding Phathom Pharmaceuticals and Replimune Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Replimune Group and Phathom Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Phathom Pharmaceuticals are associated (or correlated) with Replimune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Replimune Group has no effect on the direction of Phathom Pharmaceuticals i.e., Phathom Pharmaceuticals and Replimune go up and down completely randomly.

Pair Corralation between Phathom Pharmaceuticals and Replimune

Given the investment horizon of 90 days Phathom Pharmaceuticals is expected to under-perform the Replimune. In addition to that, Phathom Pharmaceuticals is 1.02 times more volatile than Replimune Group. It trades about -0.15 of its total potential returns per unit of risk. Replimune Group is currently generating about 0.09 per unit of volatility. If you would invest  1,037  in Replimune Group on September 6, 2024 and sell it today you would earn a total of  280.00  from holding Replimune Group or generate 27.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Phathom Pharmaceuticals  vs.  Replimune Group

 Performance 
       Timeline  
Phathom Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Phathom Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Replimune Group 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Replimune Group are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite quite conflicting basic indicators, Replimune disclosed solid returns over the last few months and may actually be approaching a breakup point.

Phathom Pharmaceuticals and Replimune Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Phathom Pharmaceuticals and Replimune

The main advantage of trading using opposite Phathom Pharmaceuticals and Replimune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Phathom Pharmaceuticals position performs unexpectedly, Replimune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Replimune will offset losses from the drop in Replimune's long position.
The idea behind Phathom Pharmaceuticals and Replimune Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Complementary Tools

Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments